| Title |
Beyond post-marketing research and MedWatch: Long-term studies of drug risks
|
|---|---|
| Published in |
Drug Design, Development and Therapy, October 2007
|
| DOI | 10.2147/dddt.s2352 |
| Pubmed ID | |
| Authors |
David B Resnik |
| Abstract |
Critics of the drug safety system have discussed many different potential reforms, ranging from mandatory registration of clinical trials to increasing the power of regulatory agencies, but few have discussed one of the most important ways of enhancing safety: increasing the number of long-term studies of medications. Long-term studies of the risks and benefits of drugs can provide useful information for regulators, healthcare professionals, and patients. Government funding agencies should lead the effort to conduct long-term studies of drugs, but private companies should also be required to lend financial support. Because cost-effectiveness is likely to be an important consideration in conducting this research, funding agencies should focus, at first, on drugs that are used to treat common, chronic conditions. |
X Demographics
The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 5% |
| Canada | 1 | 5% |
| United States | 1 | 5% |
| Unknown | 16 | 84% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 18 | 95% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 5% |
| Unknown | 20 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 24% |
| Student > Master | 3 | 14% |
| Student > Bachelor | 2 | 10% |
| Professor | 2 | 10% |
| Student > Postgraduate | 2 | 10% |
| Other | 5 | 24% |
| Unknown | 2 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 38% |
| Biochemistry, Genetics and Molecular Biology | 3 | 14% |
| Agricultural and Biological Sciences | 2 | 10% |
| Social Sciences | 2 | 10% |
| Nursing and Health Professions | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 4 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 April 2024.
All research outputs
#1,974,748
of 25,806,080 outputs
Outputs from Drug Design, Development and Therapy
#96
of 2,283 outputs
Outputs of similar age
#4,194
of 85,452 outputs
Outputs of similar age from Drug Design, Development and Therapy
#1
of 1 outputs
Altmetric has tracked 25,806,080 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,283 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 85,452 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them